Wockhardt Recalls Lisinopril Tablets Due to Complaint Investigation Failures
Wockhardt USA is recalling specific lots of Lisinopril 2.5 mg tablets because the manufacturer did not adequately investigate customer complaints.
What this means for you
Minor labeling or packaging issue, or a voluntary precautionary recall. Risk of harm is low but real — follow the manufacturer's instructions.
Our severity reasoning: The recall is classified as FDA Class II, which typically involves a situation where use of, or exposure to, the violative product may cause temporary or medically reversible health consequences. The specific deviation is a failure to investigate complaints, which is a quality control issue rather than a direct physical hazard like contamination or mislabeling of active ingredients.
Plain-English summary
Wockhardt USA LLC is recalling specific lots of Lisinopril Tablets USP, 2.5 mg, packaged in 100-count and 500-count bottles. The affected products are prescription-only medications manufactured by Wockhardt Limited in Mumbai, India, and distributed by Wockhardt USA LLC in Parsippany, New Jersey.
The recall was initiated due to Current Good Manufacturing Practice (CGMP) deviations. Specifically, the firm failed to adequately investigate customer complaints regarding the product. The affected lots include specific lot numbers and expiration dates ranging from April 2015 to February 2016, as detailed in the structured product information.
The affected products were distributed nationwide in the United States, including Puerto Rico. Consumers and healthcare providers should check their inventory for the specific lot numbers and expiration dates listed in the recall notice. If the product is found, it should be returned to the pharmacy or point of purchase for a refund or replacement.
The recalled product
- Product
- Lisinopril Tablets USP, 2.5 mg Tablets, Packaged in A) 100 Count Bottles (NDC: 64679-927-01) and B) 500 Count Bottles (NDC: 64679-927-05), Rx Only. Manufactured by: Wockhardt Limited, Mumbai, India. Distributed by: Wockhardt USA LLC 20 Waterview Blvd. Parsippany, NJ 07054 USA.
- Manufacturer
- Wockhardt Usa Inc.
- Category
- Drug — Prescription Medication
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (20)
- A) Lot #: DM10573
- Expiry: 4/30/2015
- Lot #: DM11531
- Expiry: 5/31/2015
- Lot #: DM11532
- Lot #: DM11676
- Expiry: 6/30/2015
- Lot #: DM11677
- Lot #: DM12543
- Expiry: 8/31/2015
- Lot #: DM13333
- Expiry: 11/30/2015
- Lot #: DN10272
- Expiry: 12/31/2015
- Lot #: DN10405
- Lot #: DN10446
- Expiry: 1/1/2016. B) Lot #: DM11122
- Lot #: DM11130
- Lot #: DM11533
- Lot #: DM11674
Distribution
Part of a larger recall action
This product is one of 35 recalled by Wockhardt Usa Inc. under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 35 products in this recall →Related recalls
Same manufacturer · Wockhardt Usa Inc.
See all →- LowWockhardt Recalls Enalapril Maleate Tablets Due to Impurity Failures
FDA (Drugs) · 2017-11-01
- ModerateWockhardt Recalls Lisinopril Tablets Due to Inadequate Complaint Investigations
FDA (Drugs) · 2015-08-26
- ModerateWockhardt Recalls Lisinopril Tablets Due to Inadequate Complaint Investigations
FDA (Drugs) · 2015-08-26
- ModerateWockhardt Recalls Azithromycin Tablets Due to Complaint Investigation Failures
FDA (Drugs) · 2015-07-29
- ModerateWockhardt Recalls Zolpidem Tartrate Tablets Due to Complaint Investigation Failures
FDA (Drugs) · 2015-07-29
Same hazard · cgmp deviation
See all →- SevereZicam Cold Remedy Nasal Swabs Recalled for Microbiological Testing Failures
FDA (Drugs) · 2026-09-02
- ModerateGolden State Medical Supply Recalls Carbamazepine Tablets Due to CGMP Deviations
FDA (Drugs) · 2026-08-26
- SevereShoolin Pharma Recalls Tadalafil USP Due to CGMP Deviations
FDA (Drugs) · 2026-08-19
- ModerateShoolin Pharma Recalls Tadalafil USP Due to CGMP Deviations
FDA (Drugs) · 2026-08-19
- HighShoolin Pharma Recalls Tadalafil USP Due to CGMP Deviations
FDA (Drugs) · 2026-08-19